Novartis India Latest Share Price (NOVARTIND)
TODAY IN ONE LINE
NOVARTIND fell 1.1% on light volume, lagging Nifty's 0.5% move.
With a market cap of ₹3,663.74 Cr., it trades at a P/E of 37.65. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
Novartis India flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●High Capital EfficiencyROCE of 16.2% indicating pricing power
- ●Healthy Operating MarginsOPM is structurally strong at 26.6%
- ●High Promoter HoldingPromoters hold 70.7% skin-in-the-game
- ●Steady Dividend YieldReliable 1.70% dividend yield
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.00x
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Earnings DeclineEPS (TTM) has contracted by 13.8% YoY
Latest Novartis India News
What changed recently?
Recent events, corporate actions, and announcements.
Novartis India Limited valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Novartis India Limited, framed against the sector median so the premium or discount is obvious at a glance.
Novartis India Limited trades at a P/E of 37.65× and P/B of 4.50×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
Novartis India Limited technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for Novartis India Limited — derived from the latest tape, not yesterday's close.
Novartis India Limited last traded at ₹1,486.3 with an intraday range of ₹1,474.2–₹1,503.8 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹1486.30| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 1561.20 | +74.90 | +5.04% |
| R3 | 1531.60 | +45.30 | +3.05% |
| R2 | 1517.70 | +31.40 | +2.11% |
| R1 | 1502.00 | +15.70 | +1.06% |
| PIVOT | 1488.10 | 1.80 | 0.12% |
| CURRENT | 1486.30 | — | — |
| S1 | 1472.40 | -13.90 | -0.94% |
| S2 | 1458.50 | -27.80 | -1.87% |
| S3 | 1442.80 | -43.50 | -2.93% |
| S4 | 1413.20 | -73.10 | -4.92% |
NOVARTIND is trading Below CPR, indicating Bearishness
CPR is Narrower, suggesting likely for trending moves
Day's range: ₹1474.2–₹1503.8
Trading Inside opening range
Novartis India Limited financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for Novartis India Limited — consolidated or standalone — with margins, YoY growth and key ratios inline.
Novartis India Limited reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹3,663.74 Cr. and reported EPS of ₹37.76.
Novartis India segment analysis : revenue and profit mix.
Disclosed business segments at Novartis India with their share of revenue and profit, switchable between consolidated and standalone reporting.
Novartis India discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for Novartis India Limited.
Our AI distills the core fundamental drivers supporting Novartis India Limited, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
Novartis India Limited's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
Ultra-low debt D/E 0.0000x ensures exceptional financial flexibility and stability.
Operating margin 25.97% TTM significantly outpaces many pharmaceutical sector peers.
ROE 11.60% and ROCE 16.20% reflect efficient capital deployment and returns.
Promoter holding 70.68% signals strong long-term commitment and shareholder alignment.
Beta 0.2610 indicates low systematic risk, attractive for conservative investors.
Key Risks.
Latest quarterly EPS declined 13.8% YoY despite revenue growth momentum.
Quarterly sales declined 7.95% YoY, signaling demand slowdown in key markets.
5-year revenue CAGR 0.0% reflects complete stagnation across business segments.
P/E 39.48x TTM and EV/EBITDA 19.49x suggest premium valuation multiples.
Operating cash flow ₹46.73 Cr declined 37% YoY from ₹74.57 Cr in FY25.
Flip Conditions.
Valuation risk. a P/E above 49 would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Return-quality risk. ROE below 8% would indicate weaker capital compounding.
Income thesis breaks if the dividend is cut or yield falls below 0.85%.
Novartis India Limited peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Novartis India Limited is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
Novartis India Limited chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for Novartis India Limited — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
Novartis India Limited delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Novartis India Limited over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Novartis India Limited stood at 67.3% of traded volume, against a 20-day average of 60.3%.
Novartis India announcements: results, concalls, ratings, M&A.
Filings Novartis India sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Novartis India files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 52 documents below.
Board Meeting
Novartis India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/07/2026 ,inter alia, to consider and…
Company Update
Axis Capital Ltd ("Manager to the Open Offer") has submitted to BSE a copy of Disclosure of number of Equity Shares tendered in connection with the…
Company Update
Axis Capital Ltd ("Manager to the Open Offer") has submitted to BSE a copy of Disclosure of number of Equity Shares tendered in connection with the…
Company Update
Axis Capital Ltd ("Manager to the Open Offer") has submitted to BSE a copy of Disclosure of number of Equity Shares tendered in connection with the…
Company Update
Axis Capital Ltd ("Manager to the Open Offer") has submitted to BSE a copy of Pre-Offer Advertisement in accordance with Regulation 18(7) of The…
Investor decks & rating reports.
Novartis India dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Novartis India has declared, sequenced by announce and record date.
Novartis India corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About Novartis India Limited: business, sector, key facts.
What Novartis India Limited does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Novartis India Limited operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: NOVARTIND, BSE: 500672.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- 3B Blackbio DX (3BBLACKBIO) Share PricePeer
- Abbott India (ABBOTINDIA) Share PricePeer
- Acutaas Chemicals (ACUTAAS) Share PricePeer
- Anlon Healthcare (AHCL) Share PricePeer
- Amanta Healthcare (AMANTA) Share PricePeer
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about Novartis India Limited (NOVARTIND).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Novartis India Limited (NOVARTIND)?
The current share price of Novartis India Limited (NOVARTIND) is ₹1,486.30. Today, the stock has declined by ₹15.90 (1.06%), trading in a range of ₹1,474.20 to ₹1,503.80. The stock opened at ₹1,503.80 with a trading volume of 6,845 shares.
02Is Novartis India Limited stock a good investment for long-term?
Novartis India Limited can be considered for long-term investment based on several factors. The company has a market capitalization of ₹3,663.74 Cr., P/E ratio of 37.65, ROE of 11.6%, and ROCE of 16.2%. The dividend yield stands at 1.7%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Novartis India Limited stock?
The 52-week high price of Novartis India Limited (NOVARTIND) is ₹1,780.00, while the 52-week low is ₹950.00. Currently trading at ₹1,486.30, the stock is 56.45% above its 52-week low and 16.5% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Novartis India Limited stock at the current price?
Whether to buy Novartis India Limited stock at ₹1,486.30 depends on multiple factors. The stock is currently trading with a P/E ratio of 37.65 and P/B ratio of 4.5. Today's performance shows a loss of 1.06%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Novartis India Limited and when is the next dividend?
Novartis India Limited offers a dividend yield of 1.7%, which means for every ₹100 invested at the current price of ₹1,486.30, you can expect to receive approximately ₹1.70 annually as dividends. The face value of the stock is ₹5.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Novartis India Limited?
Novartis India Limited's key financial metrics include: P/E Ratio: 37.65, P/B Ratio: 4.5, ROE: 11.6%, ROCE: 16.2%, Dividend Yield: 1.7%, EPS: ₹37.76, Book Value: ₹331.34, and Debt-to-Equity: 0. The company's market cap stands at ₹3,663.74 Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Novartis India Limited stock performing today in the market?
Novartis India Limited stock opened at ₹1,503.80 and is currently trading at ₹1,486.30, showing a decline of ₹15.90 (1.06%). The intraday high is ₹1,503.80 and low is ₹1,474.20. The trading volume stands at 6,845 shares, indicating moderate market participation today.
08What is the P/E ratio of Novartis India Limited and what does it indicate?
Novartis India Limited has a Price-to-Earnings (P/E) ratio of 37.65, which means investors are willing to pay 37.65 for every ₹1 of earnings. With an EPS of ₹37.76, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Novartis India Limited (NOVARTIND) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.